Article thumbnail

Expressions of p53 and p21 in primary gastric lymphomas.

By J. H. Go and W. I. Yang


The p21 overexpression is thought to be a consequence of the p53 induced activation of the p21 gene. The immunohistochemical evaluation of p53 and p21 can be a valuable means of assessing the functional status of the p53 gene product. We examined the overexpression of p21 and p53 proteins in primary gastric lymphomas and the correlation with prognosis. A total of 32 cases of gastric lymphomas was classified into low-grade lymphomas of mucosa-associated lymphoid tissue type (n=16) and high-grade B-cell lymphomas (n=16). In low-grade lymphomas, only one case showed p53 positivity and all cases were p21-negative. In high-grade lymphomas, seven cases were p53+/p21- (44%), one case was p53+/p21+ (6%), and eight cases were p53-/p21- (50%). The p53+/p21- cases had a much lower percentage of patients sustaining a continuous complete remission state (3/7, 43%) compared with other cases (6/7, 86%). From these results, we concluded that p21 expression is rare in primary gastric lymphomas. Therefore, p53-positive lymphomas can be assumed as having p53 mutation. And combined studies of p53 and p21 may be used as a prognostic indicator in primary gastric high-grade lymphomas

Topics: Research Article
Publisher: Korean Academy of Medical Sciences
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1995). Alteration of the p27KIP1 gene in non-Hodgkin’ s lymphomas and adult T-cell leukemia/lymphoma. Blood
  2. (2000). Apoptosis of malignant cells in Hodgkin’ s disease is related to expression of the cdk inhibitor p27KIP1.
  3. (1999). Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.
  4. (1997). Human non-Hodgkin’ s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood
  5. (1994). Malignant lymphoma of the gastrointestinal tract.
  6. (2000). P21 protein expression and cell proliferation activity in human multistep hepatocarcinogenesis.
  7. (1996). p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin’ s lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood
  8. (1994). Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol
  9. (1996). The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol